Home/Pipeline/VANADIS® BMOV

VANADIS® BMOV

Myocardial Infarction

Phase 1Active

Key Facts

Indication

Myocardial Infarction

Phase

Phase 1

Status

Active

Company

CFM Pharma

About CFM Pharma

CFM Pharma is a private, clinical-stage biotech leveraging its patented VANADIS® platform of organovanadium compounds to address significant unmet needs in acute trauma. Its lead candidate, VANADIS® BMOV, has completed Phase 1A safety studies for myocardial infarction and is Phase 1B-ready, with preclinical data showing up to 42% reduction in infarct size. The company is positioning itself for value inflection through clinical readouts and early-stage partnerships, targeting multi-billion dollar markets in cardiology, burn care, and acute kidney injury.

View full company profile

Therapeutic Areas

Cardiovascular Dermatology Nephrology

Other Myocardial Infarction Drugs

Drug	Company	Phase	Status
KEAP1/NRF2 Program	Grove Biopharma	Pre-clinical	Active
QuickProfile Cardiac Markers	LumiQuick Diagnostics	Commercial	Active
Lead Peptide Program	ResoTher Pharma	Phase 2a	Active
Myocardial Infarction Cardiac Patch	Matricelf	Preclinical	Active